These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 9664930)

  • 1. Fenofibrate for hypertriglyceridemia.
    Med Lett Drugs Ther; 1998 Jul; 40(1030):68-9. PubMed ID: 9664930
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH; Bays H; Rhyne J; Stein E; Rotenberg K; Doyle R
    Clin Ther; 2005 Jun; 27(6):715-27. PubMed ID: 16117978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which dose of omega-3 fatty acids must be taken in different cases of hypertriglyceridemia?
    Mogoş T; Dondoi C
    Rom J Intern Med; 2008; 46(1):81-6. PubMed ID: 19157275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.
    Rosenson RS; Wolff DA; Huskin AL; Helenowski IB; Rademaker AW
    Diabetes Care; 2007 Aug; 30(8):1945-51. PubMed ID: 17483155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome.
    Rosenson RS
    Am Heart J; 2008 Mar; 155(3):499.e9-16. PubMed ID: 18294485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of fenofibrate on inflammatory cytokines and blood pressure in patients with hypertriglyceridemia.
    Ye P; Li JJ; Su G; Zhang C
    Clin Chim Acta; 2005 Jun; 356(1-2):229-32. PubMed ID: 15936324
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effect of fibrates on VLDL and LDL lipoprotein composition and parameters of their oxidation in hypertriglyceridemia].
    Zeman M; Zák A; Tvrzická E; Konárková M; Stípek S
    Cas Lek Cesk; 2002 Apr; 141(7):211-6. PubMed ID: 12053756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fenofibrate can increase serum creatinine levels in renal insufficiency.
    Paul S; Mohan V
    J Assoc Physicians India; 2006 Apr; 54():337. PubMed ID: 16944623
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical pharmacokinetics of fenofibrate.
    Telford M
    Curr Med Res Opin; 2003; 19(2):139; author reply 139-40. PubMed ID: 12740159
    [No Abstract]   [Full Text] [Related]  

  • 10. Myopathy caused by a combination rosuvastatin and fenofibrate.
    Dedhia V; Munsi SC
    J Assoc Physicians India; 2007 Feb; 55():152-3. PubMed ID: 17571748
    [No Abstract]   [Full Text] [Related]  

  • 11. Fenofibrate-induced myopathy.
    Ghosh B; Sengupta S; Bhattacharjee B; Majumder A; Sarkar SB
    Neurol India; 2004 Jun; 52(2):268-9. PubMed ID: 15269493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new formulation of fenofibrate: suprabioavailable tablets.
    Guichard JP; Blouquin P; Qing Y
    Curr Med Res Opin; 2000; 16(2):134-8. PubMed ID: 10893657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Fenofibrate, efficacy and tolerance in long-term treatment (author's transl)].
    Fromantin M; Gautier D; Quatre JM; Bon R
    Therapie; 1981; 36(4):473-6. PubMed ID: 7292431
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
    Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Cariolou M; Ganotakis ES; Mikhailidis DP; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):211-21. PubMed ID: 17056835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD).
    Bailey CJ
    Diabet Med; 2006 Feb; 23(2):109-12. PubMed ID: 16433706
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of fenofibrate on C-reactive protein levels in hypertriglyceridemic patients.
    Kim CJ
    J Cardiovasc Pharmacol; 2006 Jun; 47(6):758-63. PubMed ID: 16810076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reductions in plasma cholesterol levels after fenofibrate treatment are negatively correlated with resistin expression in human adipose tissue.
    Jové M; Planavila A; Cabrero A; Novell F; Ros E; Zambón D; Laguna JC; Carrera MV
    Metabolism; 2003 Mar; 52(3):351-5. PubMed ID: 12647275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans.
    Bergman AJ; Murphy G; Burke J; Zhao JJ; Valesky R; Liu L; Lasseter KC; He W; Prueksaritanont T; Qiu Y; Hartford A; Vega JM; Paolini JF
    J Clin Pharmacol; 2004 Sep; 44(9):1054-62. PubMed ID: 15317833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency.
    Ruel IL; Lamarche B; Mauger JF; Badellino KO; Cohn JS; Marcil M; Couture P
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2600-7. PubMed ID: 16224048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fenofibrate: treatment of hyperlipidemia and beyond.
    Rosenson RS
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1319-30. PubMed ID: 19018684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.